Allergic Rhinitis and Pharmacological Management in Elite Athletes

ANTTI ALARANTA1, HANNU ALARANTA2, MARKKU HELIOVAAARA3, PIRKKO ALHA3, PETRI PALMU4, and ILKKA HELENIUS5

1Faculty of Pharmacy, University of Helsinki, Helsinki, FINLAND; 2Käpylä Rehabilitation Centre, Helsinki, FINLAND; 3National Public Health Institute, Helsinki, FINLAND; 4Faculty of Social Sciences, University of Helsinki, Helsinki, FINLAND; and 5Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, FINLAND

ABSTRACT
ALARANTA, A., H. ALARANTA, M. HELIOVAAARA, P. ALHA, P. PALMU, and I. HELENIUS. Allergic Rhinitis and Pharmacological Management in Elite Athletes. Med. Sci. Sports Exerc., Vol. 37, No. 5, pp. 707–711, 2005. Introduction: Only a few studies have examined the occurrence of atopy and clinically apparent allergic disease and their pharmacological management in elite athletes. The aim of the study was to assess the frequency of allergic rhinitis and the use of antiallergic medication within the subgroups of elite athletes as compared with a representative sample of young adults of the same age. Methods: A cross-sectional survey was carried out in 2002. All the athletes (N = 494) financially supported by the National Olympic Committee comprised the study group. Of them, 446 (90.3%) filled in a structured questionnaire concerning asthma and allergies, the use of medication, characteristics of sport activities, and smoking habits. A representative sample of Finnish young adults (N = 1504) served as controls. Results: The endurance athletes reported physician-diagnosed allergic rhinitis more often (36.1%) than other athletes (23.4%) or control subjects (20.2%). The use of antiallergic medication was reported by 33.3, 15.7, and 15.6% of those, respectively. Among both athletes and controls, females reported the use of antiallergic medication more often than males. Only half of those athletes reporting allergic rhinitis had used antiallergic medication during the past year. After adjusting for age and sex, OR (95% CI) for allergic rhinitis and the use of antiallergic medication were 2.24 (1.48–3.39) and 2.79 (1.82–4.28), respectively, in endurance athletes as compared with the controls. Conclusions: Endurance athletes have physician-diagnosed allergic rhinitis, and they use antiallergic medication more often than athletes in other events or control subjects. Only half of those athletes reporting allergic rhinitis take antiallergic medication. More attention needs to be paid to the optimal management of allergic rhinitis, especially in highly trained endurance athletes. Key Words: ANTIALLERGIC MEDICATION, ALLERGIC RHINOCONJUNCTIVITIS, ANTIHISTAMINES, INTRANASAL CORTICOSTEROIDS, ENDURANCE ATHLETE

SPORT EXERCISE MAY INCREASE VENTILATION UP TO 200 L·MIN⁻¹ FOR SHORT PERIODS OF TIME IN SPEED AND POWER ATHLETES AND FOR LONGER PERIODS IN ENDURANCE ATHLETES (8). WHEN THE VENTILATION LEVEL EXCEEDS ABOUT 30 L·MIN⁻¹, A SHIFT OCCURS FROM NASAL BREATHING TO COMBINED MOUTH AND NASAL BREATHING (3). THIS SHIFT RESULTS IN A GREATER DEPOSITION OF AIRBORNE ALLERGENS AND OTHER INHALED PARTICLES INTO THE ATHLETE'S LOWER AIRWAYS; IN ADDITION, INCOMPLETELY CONDITIONED AIR MAY REACH THE MUCCOUS MEMBRANES OF THE LOWER AIRWAYS (18). ATHLETES WHO PARTICIPATE IN SUMMER EVENTS ARE INTENSIVELY EXPOSED TO AIRBORNE ALLERGENS DURING THEIR TRAINING AND COMPETITIONS, WHEREAS WINTER SPORT ATHLETES ARE EXPOSED TO COLD AIR (20). SWIMMERS ARE EXPOSED TO CHLORINE COMPOUNDS. IN SKIERS (8,15,19), THE ASSOCIATION BETWEEN ATOPY, RESPIRATORY ALLERGY, AND ASTHMA HAS NOT BEEN DEMONSTRATED TO BE AS CLEAR AS IN SUMMER SPORT ATHLETES (9,10). INDEED, ALLERGIC RHINITIS (AR) AND ATOPY ARE MORE COMMON IN ENDURANCE ATHLETES COMPETING IN SUMMER EVENTS AS COMPARED WITH CONTROL SUBJECTS (9), WHEREAS THE OCCURRENCE OF ATOPY IN SKIERS IS SIMILAR AS IN CONTROL SUBJECTS (19).

NASAL MUCOSAL SWELLING MAY LEAD TO COMPROMISED DRAINAGE OF THE RELATED ANATOMICAL SYSTEMS, WHICH MAY LEAD TO ACUTE OR CHRONIC INFECTION (13). CHRONIC AR IS ASSOCIATED WITH MANY COMPLICATIONS. NASAL OBSTRUCTION ON A LONG-TERM BASIS OFTEN LEADS TO SNEEZING, SLEEP DISTURBANCE, HEADACHES, AND FATIGUE, ALL OF WHICH WILL IMPAIR A PERSON'S QUALITY OF LIFE. IMPAIRED SLEEP, TOGETHER WITH IRRITABILITY CAUSED BY THIS CONDITION, CAN HAVE A SIGNIFICANT IMPACT ON A PERSON'S QUALITY OF LIFE BY LEADING TO POOR PERFORMANCE AND CHRONIC...
tiredness. When AR affects elite athletes, however, these quality-of-life issues make it particularly troublesome, and it may cause significant impairment in their athletic performances. During exercise, minute ventilation increases, which brings the nasal passages into contact with greater volumes of air and therefore allergens, so symptoms are commonly experienced during exercise. For example, a short burst of sprinting requires combined mouth and nasal breathing for optimal performance, so a change in the individual’s pattern of breathing because of nasal obstruction may affect performance. Untreated AR may also compromise the treatment of asthma in elite athletes (4). Furthermore, several studies have shown that AR is underrecognized and certainly undertreated in elite athletes (7,14). It has been suggested that strong and repeated exposure to airborne allergens causes not only bronchial symptoms but also AR in elite summer sport athletes (20).

The pharmacological management of AR has to comply with antidoping regulations. The goal of the therapy is optimum symptom control while minimizing the detrimental influences on performance from adverse effects. Recently, caffeine, pseudoephedrine, and phenylpropanolamine were declassified by the WADA. This facilitates the pharmacological care of AR in elite athletes and removes the concern for the positive test results when these substances are used unintentionally for the management of AR. The results of the IOC accredited laboratories show that nearly one third of the positive results for stimulants were for these three substances in 2002 (IOC statistics 2002, Overview on the results reported by the IOC accredited laboratories, http://multimedia.olympic.org/pdf/en_report_632.pdf).

Whereas the impact of exercise-induced asthma and increased bronchial responsiveness on athletes’ performance has been studied extensively, only a few studies have examined the occurrence of atopy and clinically apparent allergic disease and their pharmacological management in elite athletes. The aim of the study was to assess the frequency of AR, other allergic conditions, and the use of antiallergic medication within the different groups of sport activities in a large sample of Finnish top elite athletes. These athletes were also compared with a representative sample of young adults of the same age.

The reference group consisted of all persons aged 18–29 yr (N = 1894) from the Finnish National Health Survey Health 2000, coordinated by the National Public Health Institute. A nationally representative two-stage cluster sample was drawn, which consisted of 10,000 persons and 80 regions (municipalities or groups of municipalities with joint primary care). The sample included inhabitants of all the 15 largest cities and towns. The sub-study of younger adults aged 18–29 consisted of a computer-aided health interview carried out during the spring and summer of 2001. The final size of the sample of those aged 18–29 was 1876, of which 1504 (80.2%) participated in the health interview. The data was collected, stored, analyzed, and reported anonymously according to the law of data protection in Finland.

**Questionnaire.** Questions concerned asthma, exercise-induced bronchial symptoms, the use of asthma and allergy medication, the characteristics of sport activities, educational level, and smoking habits (1). The subjects were asked whether they had a disturbing allergy that had been diagnosed by a physician. When the subject responded affirmatively to the question, the subject was further asked whether the condition was AR, allergic conjunctivitis, atopic eczema, or other. The subjects were also asked whether they had any current medication for their condition.

They were asked to complete the questionnaire at their national team camps during the study period, and if they were absent, the questionnaire was sent to them by mail. Of the 494 athletes, 446 (90.3%) filled in a structured questionnaire after accepting written informed consent. The athletes were divided into four groups according to their type of sport. The four groups were speed and power sport athletes, endurance athletes, athletes in motor skills demanding events, and team sport athletes. The characteristics of the four study groups are given in the Table 1. The inclusion criteria and methods employed have been described in details previously in this journal (1).

**Control subjects.** The reference group consisted of all persons aged 18–29 yr (N = 1894) from the Finnish National Health Survey Health 2000, coordinated by the National Public Health Institute. A nationally representative two-stage cluster sample was drawn, which consisted of 10,000 persons and 80 regions (municipalities or groups of municipalities with joint primary care). The sample included inhabitants of all the 15 largest cities and towns. The study of younger adults aged 18–29 consisted of a computer-aided health interview carried out during the spring and summer of 2001. The final size of the sample of those aged 18–29 was 1876, of which 1504 (80.2%) participated in the health interview. The data was collected, stored, analyzed, and reported anonymously according to the law of data protection in Finland.

**Response rate (%)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 90.3%
  - Endurance Events (N = 108): 90.8%
  - Motor Skills-Demanding Events (N = 73): 82.0%
  - Team Sport Events (N = 152): 95.6%
  - Controls (N = 1904/1976): 80.2%

**Mean (SD) training amount (h·wk⁻¹)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 15.4 (6.1)
  - Endurance Events (N = 108): 17.3 (5.9)
  - Motor Skills-Demanding Events (N = 73): 15.1 (7.4)
  - Team Sport Events (N = 152): 14.1 (6.3)
  - Controls (N = 1904/1976): 9.6

**Mean (SD) duration of active sport career (yr)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 12.2 (3.7)
  - Endurance Events (N = 108): 12.4 (4.6)
  - Motor Skills-Demanding Events (N = 73): 11.9 (5.0)
  - Team Sport Events (N = 152): 10.8 (4.1)
  - Controls (N = 1904/1976): —

**Mean (SD) age (yr)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 23.0 (4.5)
  - Endurance Events (N = 108): 23.6 (4.0)
  - Motor Skills-Demanding Events (N = 73): 23.6 (5.6)
  - Team Sport Events (N = 152): 21.6 (5.6)
  - Controls (N = 1904/1976): 23.4 (5.5)

**Sex (men/women)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 261/185
  - Endurance Events (N = 108): 62/46
  - Motor Skills-Demanding Events (N = 73): 45/28
  - Team Sport Events (N = 152): 72/80
  - Controls (N = 1904/1976): 766/738

**Events (N)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 15.4 (6.1)
  - Endurance Events (N = 108): 17.3 (5.9)
  - Motor Skills-Demanding Events (N = 73): 15.1 (7.4)
  - Team Sport Events (N = 152): 14.1 (6.3)
  - Controls (N = 1904/1976): 9.6

**Response rate (%)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 90.3%
  - Endurance Events (N = 108): 90.8%
  - Motor Skills-Demanding Events (N = 73): 82.0%
  - Team Sport Events (N = 152): 95.6%
  - Controls (N = 1904/1976): 80.2%

**Sex (men/women)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 261/185
  - Endurance Events (N = 108): 62/46
  - Motor Skills-Demanding Events (N = 73): 45/28
  - Team Sport Events (N = 152): 72/80
  - Controls (N = 1904/1976): 766/738

**Events (N)**

- **All Athletes (N = 446/494)**
  - Speed and Power Events (N = 113): 15.4 (6.1)
  - Endurance Events (N = 108): 17.3 (5.9)
  - Motor Skills-Demanding Events (N = 73): 15.1 (7.4)
  - Team Sport Events (N = 152): 14.1 (6.3)
  - Controls (N = 1904/1976): 9.6
using a logistic regression model (SPSS 10.0 software). Age, sex, and type of sport were included as independent covariates in the analysis.

The sample-size requirement was calculated using a study power of 80%, a Type I error $\alpha$ of 0.05, and an estimated prevalence of 25 and 15% for AR in the athlete and control group, respectively (9). A total of 249 study subjects in both groups were required to identify a 10% difference in prevalence rates between these groups.

**RESULTS**

No statistical difference was found in the occurrence of a disturbing allergy (32.1 vs 30.1%; Table 2), or in the age- and sex-adjusted OR between athletes and controls (OR, 1.12; 95% CI, 0.89–1.41). A physician-diagnosed AR was reported by 26.5% (118 of 446) of the athletes and by 20.2% (303 of 1503) of the controls (Table 2). After adjusting for age, and sex, the OR (95% CI) for physician diagnosed AR was significantly higher among endurance athletes as compared with controls (OR, 2.24; 95% CI, 1.48–3.39; Table 4).

The athletes reported the use of antiallergic medication more often than the controls did (20.0 vs 15.6%; OR, 1.42; 95% CI, 1.08–1.87). A total of 12.6% (353 of 283) of the controls reported using antiallergic medication during the last 7 d. Of the athletes 4.9% (34/446) and 2.3% (34/1503) of the controls reported using antiallergic medication.

The most commonly used antiallergy drugs in all study groups were oral antihistamines, followed by intranasal corticosteroids. A significant difference was observed in the frequency of oral antihistamine use between different sport events, with the endurance athletes reporting treatment most often. After adjusting for age and sex, the OR (95% CI) for the use of oral antihistamines was significantly higher among endurance athletes than in the general population (OR, 2.52; 95% CI, 1.54–4.12, Table 4). Among those with a history of any allergy, no significant difference in the use of antiallergic medication was found between various groups of athletes and the general population.

A total of 55.1% (65 of 118) of those athletes and 53.5% (162 of 303) of the controls having physician-diagnosed rhinitis reported using antiallergic medication. Female athletes with physician diagnosed AR used antiallergic medication more often than male athletes (65.3% (32 of 49) vs 47.8% (33 of 69)). Of the athletes reporting AR, 34.7% (41 of 118) also had physician-diagnosed asthma, whereas 6.4% (21 of 328) of those athletes who did not report AR had asthma.

**TABLE 2. Prevalence (%) of physician-diagnosed disturbing allergy, AR, allergic conjunctivitis, and atopic eczema in the study groups.**

<table>
<thead>
<tr>
<th></th>
<th>All athletes</th>
<th>Women</th>
<th>Men</th>
<th>Summer events</th>
<th>Winter events</th>
<th>Speed and power athletes</th>
<th>Endurance athletes</th>
<th>Motor skill–demanding events</th>
<th>Team sport athletes</th>
<th>Controls</th>
<th>Women</th>
<th>Men</th>
<th>Winter events</th>
<th>Summer events</th>
<th>Events</th>
<th>Team sport athletes</th>
<th>Controls</th>
<th>Women</th>
<th>Men</th>
<th>Winter events</th>
<th>Summer events</th>
<th>Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy</td>
<td>32.1 (143/446)</td>
<td>30.8 (57/185)</td>
<td>33.0 (86/261)</td>
<td>32.7 (87/266)</td>
<td>31.1 (56/180)</td>
<td>27.4 (31/113)</td>
<td>43.5 (47/108)</td>
<td>35.6 (25/74)</td>
<td>25.7 (39/152)</td>
<td>30.1 (453/1503)</td>
<td>31.0 (229/738)</td>
<td>29.3 (224/765)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhino</td>
<td>26.5 (118/446)</td>
<td>26.5 (49/185)</td>
<td>26.4 (69/261)</td>
<td>27.4 (73/266)</td>
<td>25.0 (45/180)</td>
<td>20.4 (23/113)</td>
<td>36.1 (39/108)</td>
<td>27.4 (20/73)</td>
<td>23.7 (36/152)</td>
<td>20.2 (303/1503)</td>
<td>20.3 (150/738)</td>
<td>20.0 (153/765)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>4.9 (9/185)</td>
<td>4.9 (8/185)</td>
<td>2.7 (7/261)</td>
<td>3.0 (8/266)</td>
<td>4.8 (8/180)</td>
<td>1.8 (2/113)</td>
<td>4.6 (5/108)</td>
<td>4.1 (3/75)</td>
<td>3.9 (6/152)</td>
<td>5.6 (87/1503)</td>
<td>6.5 (48/738)</td>
<td>5.1 (39/765)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eczema</td>
<td>2.2 (16/446)</td>
<td>2.2 (16/446)</td>
<td>0 (0/266)</td>
<td>0 (0/266)</td>
<td>0 (0/180)</td>
<td>0 (0/113)</td>
<td>2.8 (3/108)</td>
<td>1.4 (1/73)</td>
<td>1.3 (2/152)</td>
<td>0.8 (2/261)</td>
<td>0 (0/113)</td>
<td>0 (0/113)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any Antiallergy</td>
<td>5.6 (25/446)</td>
<td>7.0 (13/185)</td>
<td>4.6 (12/261)</td>
<td>4.9 (13/266)</td>
<td>6.7 (12/180)</td>
<td>2.7 (3/113)</td>
<td>9.3 (10/108)</td>
<td>9.6 (7/73)</td>
<td>3.3 (5/152)</td>
<td>8.4 (126/1503)</td>
<td>12.3 (91/738)</td>
<td>4.6 (35/765)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 3. Prevalence (%) of the use of antiallergic medication during the previous 12 months.**

<table>
<thead>
<tr>
<th></th>
<th>Oral Antihistamines</th>
<th>Intranasal Corticosteroids</th>
<th>Sympathomimetcs</th>
<th>Antiallergic Nasal Sprays without Corticosteroids</th>
<th>Antiallergic Eyedrops</th>
<th>Any Antiallergic Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>All athletes</td>
<td>13.7 (61/446)</td>
<td>6.1 (27/446)</td>
<td>1.3 (6/446)</td>
<td>1.3 (6/446)</td>
<td>2.2 (10/446)</td>
<td>20.0 (89/446)</td>
</tr>
<tr>
<td>Women</td>
<td>17.3 (32/185)</td>
<td>8.6 (16/185)</td>
<td>0.5 (1/185)</td>
<td>1.6 (3/185)</td>
<td>4.3 (8/185)</td>
<td>25.9 (48/185)</td>
</tr>
<tr>
<td>Men</td>
<td>11.1 (29/261)</td>
<td>4.2 (11/261)</td>
<td>1.9 (5/261)</td>
<td>1.1 (3/261)</td>
<td>0.8 (2/261)</td>
<td>15.7 (41/261)</td>
</tr>
<tr>
<td>Summer events</td>
<td>13.5 (36/266)</td>
<td>4.9 (13/266)</td>
<td>2.3 (6/266)</td>
<td>0.4 (1/266)</td>
<td>1.5 (4/266)</td>
<td>18.0 (48/266)</td>
</tr>
<tr>
<td>Winter events</td>
<td>13.9 (25/180)</td>
<td>7.8 (14/180)</td>
<td>0</td>
<td>2.8 (5/180)</td>
<td>3.3 (6/180)</td>
<td>22.3 (41/180)</td>
</tr>
<tr>
<td>Speed and power athletes</td>
<td>11.5 (13/113)</td>
<td>5.3 (6/113)</td>
<td>2.7 (3/113)</td>
<td>0.9 (1/113)</td>
<td>1.8 (2/113)</td>
<td>16.8 (19/113)</td>
</tr>
<tr>
<td>Motor skill–demanding</td>
<td>8.2 (6/73)</td>
<td>2.7 (2/73)</td>
<td>1.4 (1/73)</td>
<td>0</td>
<td>1.4 (1/73)</td>
<td>12.3 (9/73)</td>
</tr>
<tr>
<td>Team sport athletes</td>
<td>10.5 (16/152)</td>
<td>5.9 (9/152)</td>
<td>0</td>
<td>1.3 (2/152)</td>
<td>2.0 (3/152)</td>
<td>16.4 (25/152)</td>
</tr>
<tr>
<td>Controls</td>
<td>11.0 (166/1503)</td>
<td>3.6 (54/1503)</td>
<td>3.1 (46/1503)</td>
<td>0.5 (7/1503)</td>
<td>1.8 (27/1503)</td>
<td>15.6 (235/1503)</td>
</tr>
<tr>
<td>Women</td>
<td>11.9 (88/738)</td>
<td>4.7 (35/738)</td>
<td>3.9 (29/738)</td>
<td>0.5 (4/738)</td>
<td>2.4 (22/738)</td>
<td>17.5 (129/738)</td>
</tr>
<tr>
<td>Men</td>
<td>10.2 (78/765)</td>
<td>2.5 (19/765)</td>
<td>2.2 (17/765)</td>
<td>0.4 (3/765)</td>
<td>0.7 (5/765)</td>
<td>13.9 (106/765)</td>
</tr>
</tbody>
</table>
Untreated AR may severely weaken athletes' maximal exercise performance. In accordance with that fact and previous studies, the current study showed that physician-diagnosed AR and the use of antiallergic medication are significantly more prevalent in the elite endurance athletes than among other athletes or the general population. However, the prevalence of allergic conditions other than AR did not differ between various groups of athletes and the general population. Nearly half of the athletes with an AR diagnosis did not take antiallergic medication. Thus, undertreatment may also be a problem for elite athletes.

**DISCUSSION**

Untreated AR may severely weaken athletes’ maximal exercise performance. In accordance with that fact and previous studies, the current study showed that physician-diagnosed AR and the use of antiallergic medication are significantly more prevalent in the elite endurance athletes than among other athletes or the general population. However, the prevalence of allergic conditions other than AR did not differ between various groups of athletes and the general population. Nearly half of the athletes with an AR diagnosis did not take antiallergic medication. Thus, undertreatment may also be a problem for elite athletes.

**Validity of the data.** A structured questionnaire was used to evaluate the prevalence of AR and the use of antiallergic medication by elite athletes as compared with a large control population representing Finnish people of the same age. Response rate was excellent exceeding 90% for the athletes and 80% for the control subjects. The sample-size requirement was calculated using study power of 80% and Type I α error of 0.05. This gave 249 study subjects in both groups, which we managed to recruit.

In the present study, 20% of the control population reported having a physician-diagnosed AR. This corresponds well with a previous study in our country. According to Vartiainen et al. (21), a lifetime history of hay fever was reported by 21.9% of the males and 12.3% of the females. Symptoms of rhinitis were more frequent in the subgroup of endurance athletes than in other groups. These findings correspond well with our results and can be explained by the athletes’ increased exposure to airborne allergens especially in endurance events.

**Comparison with earlier studies.** Helbling et al. (7) surveyed 2961 elite Swiss athletes (response rate 70%) participating in 68 sports. A total of 16.8% of the athletes indicated that they had AR, and of these 59% needed medication during the pollen season. In the present study, 26.5% of the athletes reported AR, with 55% having medication for it.

Helenius et al. (9) found that clinical pollen allergy (a positive skin-prick test (SPT) and symptoms of seasonal allergic rhinoconjunctivitis (ARC) affected one third of the endurance athletes competing in summer events. Katelaris et al. (13) determined the incidence of seasonal ARC in a large sample of Australian elite athletes (N = 977). Of these, 49.5% had symptoms of ARC, 23% a history of asthma, and 10% of eczema. A total of 56% had a positive SPT to at least one allergen tested, and 34% to at least one seasonal allergen. Of the athletes, 25% met the criteria for a diagnosis of seasonal ARC (a positive SPT to at least one seasonal allergen and the presence of at least two symptoms of ARC).

Maiolo et al. (17) studied asthma and atopy in 1060 Italian athletes who were trying out for a position on the Italian Olympic Team for the Sydney 2000 Olympic Games. Of the studied athletes, 18.3% reported symptoms of atopy. No significant gender differences were observed. A total of 14.5% of the athletes reported being diagnosed for AR (15.5% of the males and 12.3% of the females). Symptoms of rhinitis were more frequent in the subgroup of endurance athletes than in the other groups. These findings correspond well with our results and can be explained by the athletes’ increased exposure to airborne allergens especially in endurance events.

**TABLE 4. Logistic regression model on physician-diagnosed disturbing allergy, AR, and antiallergic medication used during the previous 12 months after adjusting for age and sex.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Disturbing Allergy</th>
<th>Allergic Rhinitis</th>
<th>Oral Antihistamines</th>
<th>Intranasal</th>
<th>Any Antiallergic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95% CI</td>
<td>OR 95% CI</td>
<td>OR 95% CI</td>
<td>Corticosteroids</td>
<td>Medication</td>
</tr>
<tr>
<td>Age (yr)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Under 21</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>21–24</td>
<td>1.07 0.83–1.37</td>
<td>1.04 0.79–1.37</td>
<td>1.27 0.87–1.84</td>
<td>0.65 0.35–1.21</td>
<td>1.18 0.86–1.62</td>
</tr>
<tr>
<td>Over 24</td>
<td>1.17 0.91–1.49</td>
<td>1.07 0.81–1.41</td>
<td>1.33 0.92–1.92</td>
<td>1.49 0.88–2.52</td>
<td>1.33 0.98–1.81</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Men</td>
<td>0.96 0.79–1.17</td>
<td>0.99 0.80–1.23</td>
<td>0.78 0.59–1.04</td>
<td>0.50 0.32–0.79</td>
<td>0.69 0.54–0.88</td>
</tr>
<tr>
<td>Type of sports</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None (controls)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Speed and power athletes</td>
<td>0.89 0.58–1.38</td>
<td>1.01 0.63–1.63</td>
<td>1.07 0.58–1.97</td>
<td>1.69 0.70–4.06</td>
<td>1.18 0.70–1.98</td>
</tr>
<tr>
<td>Endurance athletes</td>
<td>1.79 1.21–2.67</td>
<td>2.24 1.48–3.39</td>
<td>2.52 1.54–4.12</td>
<td>2.75 1.35–5.38</td>
<td>2.79 1.82–4.28</td>
</tr>
<tr>
<td>Motor skill–demanding events</td>
<td>1.33 0.81–2.19</td>
<td>1.51 0.89–2.56</td>
<td>0.76 0.32–1.79</td>
<td>0.77 0.18–3.22</td>
<td>0.81 0.40–1.66</td>
</tr>
<tr>
<td>Team sport athletes</td>
<td>0.82 0.56–1.21</td>
<td>1.25 0.84–1.89</td>
<td>0.92 0.57–1.71</td>
<td>1.50 0.77–3.34</td>
<td>1.11 0.70–1.74</td>
</tr>
</tbody>
</table>
durability events (9). In contrast, the prevalence of allergic conjunctivitis did not differ between athletes and controls in the present study. This could be explained by the fact that athletes’ conjunctivae do not receive such an increase of airborne allergens as airway mucosal lining membrane does.

The upper respiratory tract functions as a physical filter, heat exchanger, and humidifier for inhaled air. Thus, alteration of upper airway function is expected to result in alteration of lower airway function. According to Volcheck (22), AR should be carefully assessed and aggressively controlled in order to prevent the development of asthma or as integral part of asthma treatment. Several epidemiologic studies have shown an association between AR and asthma (16). Guerra et al. (6) reported, after controlling for age, sex, smoking status, and atopic status, that rhinitis increased the risk of asthma threefold. In the allergy report from the American Academy of Allergy, Asthma, and Immunology, it was estimated that up to 38% of patients with AR have asthma (2). In the present study, 34.7% of the athletes with AR reported having asthma, whereas only 6.4% of the athletes not reporting AR had asthma.

Pharmacological management. No studies have evaluated in detail the use of antiallergic medication by elite athletes. Treatment of AR could include avoiding allergens (usually not possible for athletes), taking intranasal corticosteroids, short-term decongestants, oral or topical H1 receptor antagonists (antihistamines), intranasal cromoglycate, anticholinergic agents, or by undergoing allergen immunotherapy (12).

Weiner et al. (23) conducted a meta-analysis of 16 evaluable trials. Their analysis strongly indicates that intranasal corticosteroids are significantly more effective at relieving nasal blockage, discharge, itch, and postnasal drip than are oral antihistamines. Intranasal corticosteroids were also more effective at relieving sneezing and in reducing total nasal symptoms than were the oral antihistamines, but there was significant heterogeneity between the studies. Carrozz et al. (5) reported that preventive treatment with intranasal corticosteroids, significantly improved symptoms of AR, quality of life, and performance of Australian elite athletes. In the present study, 6% of the athletes and 3.6% of the control subjects reported they had used intranasal corticosteroids.

In conclusion, endurance athletes have physician-diagnosed AR, and they use antiallergic medication more often than athletes in other events or control subjects. Female athletes use antiallergic medication more frequently than male athletes. Only half of those athletes reporting AR take antiallergic medication. More attention thus needs to be paid to the optimal management of AR in highly trained athletes.

The study was supported by Finnish National Olympic Committee, Finnish Ministry of Education, and Finnish Sports Research Foundation.

REFERENCES


